Venous Thromboembolism - 7MM Market Insights, Epidemiology, And Market Forecast - 2036 Rising VTE Burden And Factor XI Innovation Drive Growth Opportunities
The venous thromboembolism market is expected to expand through 2036, driven by an aging population, rising obesity rates, sedentary lifestyles, chronic disease prevalence, hospitalizations, cancer treatment, and growing surgical volumes. The number of affected adults in the United States could nearly double over the coming decades, increasing demand for thrombosis prevention, effective anticoagulation, and long-term disease management.
The "Venous Thromboembolism - Market Insights, Epidemiology and Market Forecast - 2036" report provides comprehensive coverage of the United States, EU4 countries comprising Germany, Spain, Italy, and France, the United Kingdom, and Japan. It analyzes historical and forecasted epidemiology, treatment practices, patient burden, market size, therapy uptake, competitive positioning, unmet medical needs, and commercial opportunities from 2022-2036.
Key Venous Thromboembolism Market Trends
- The United States accounted for the largest share of the 7MM venous thromboembolism market in 2025 and is projected to maintain robust growth through 2036. Direct oral anticoagulants have expanded the treated population by offering fixed dosing and reduced monitoring requirements compared with traditional anticoagulants. ELIQUIS is the leading therapy, supported by strong efficacy, a favorable safety profile, oral administration, extensive clinical evidence, and broad physician adoption. Concerns regarding bleeding continue to contribute to anticoagulant underutilization, particularly among high-bleeding-risk patients. Recurrent events and persistent long-term complications reinforce the need for improved risk stratification and safer extended anticoagulation strategies. Pipeline development is increasingly focused on factor XI-targeted anticoagulants and innovative thrombolytic approaches designed to improve outcomes while limiting bleeding risk.
Epidemiology and Patient Burden
Venous thromboembolism remains a major cause of morbidity and mortality. In the United States, up to 900,000 people develop the condition annually, with an estimated 60,000-100,000 associated deaths each year. Approximately half of all episodes are linked to hospitalization or surgery during the preceding three months. Incidence increases significantly with age and may reach 1 per 100 annually among individuals over 80 years old.
Women face elevated risk during younger adulthood because of pregnancy and combined hormonal contraceptive use. Additional risk factors include prolonged immobility, cancer, obesity, inherited thrombophilia, cardiovascular disorders, and critical illness. Diagnosis typically combines clinical prediction tools, D-dimer testing, compression ultrasonography, and computed tomography pulmonary angiography.
Current Venous Thromboembolism Treatment Landscape
Anticoagulation remains central to preventing clot extension, embolization, and recurrence. Direct oral anticoagulants such as apixaban, rivaroxaban, dabigatran, and edoxaban are widely used. Low-molecular-weight heparins and vitamin K antagonists retain important roles in selected clinical settings, including cancer-associated thrombosis and cases requiring parenteral anticoagulation. Severe or high-risk disease may require thrombolysis, catheter-directed intervention, or surgical thrombectomy.
Apixaban, marketed as ELIQUIS by Bristol Myers Squibb, is expected to remain the market leader during the forecast period. Bristol Myers Squibb reported that US apixaban revenue increased by 6% in 2025, primarily because of higher demand. Dabigatran etexilate, marketed as PRADAXA by Boehringer Ingelheim, continues to provide an established oral option, although competition from factor Xa inhibitors has limited its growth. Dalteparin sodium, marketed as FRAGMIN, maintains a targeted role in hospitalized patients and selected cases of cancer-associated thrombosis.
Venous Thromboembolism Pipeline and Emerging Therapies
The development pipeline remains limited but includes potentially differentiated candidates from Regeneron Pharmaceuticals and Bayer.
- REGN7508: Regeneron Pharmaceuticals is evaluating this factor XI monoclonal antibody in Phase III development for venous thromboembolism prevention. Phase II ROXI-VTE studies reported superiority to enoxaparin and non-inferiority to apixaban for postoperative prevention following total knee arthroplasty. No major bleeding events were observed in Phase I or Phase II studies. The ROXI-APEX Phase III trial is comparing REGN7508 with apixaban and enoxaparin, while initial pivotal data are anticipated from 2027. BAY3018250: Bayer is developing this investigational thrombolytic agent for symptomatic proximal deep vein thrombosis. The candidate is intended to promote clot dissolution and may support faster restoration of venous blood flow while reducing long-term complications such as post-thrombotic syndrome.
REGN7508 could achieve meaningful uptake if clinical development confirms effective thrombosis prevention with a reduced bleeding burden. Adoption may be strongest among patients whose bleeding risk limits conventional anticoagulant use. BAY3018250 is expected to have more targeted initial uptake in acute deep vein thrombosis and specialized treatment centers, with broader adoption dependent on clinical efficacy and safety results.
Unmet Needs and Commercial Opportunities
- Safer anticoagulants with lower bleeding risk Improved prevention of recurrent venous thromboembolism Better management of persistent long-term complications Additional therapies for high-bleeding-risk patients More effective patient selection and risk stratification Improved adherence, access, and long-term treatment persistence
The introduction of factor XI inhibitors and clot-dissolving therapies could reshape the competitive landscape by providing differentiated safety and efficacy profiles. Pricing, reimbursement, route of administration, dosing frequency, market entry timing, and physician confidence will influence adoption. Established oral anticoagulants are expected to retain a strong position, while emerging products will need to demonstrate clear clinical and economic value.
Report Coverage and Strategic Analysis
The report evaluates venous thromboembolism epidemiology, market size, patient population forecasts, treatment algorithms, drug uptake, pricing trends, peak patient share, and therapy-specific revenue potential. It also reviews clinical trial data, mechanisms of action, regulatory activity, patents, collaborations, and strategic partnerships involving Bristol Myers Squibb, Boehringer Ingelheim, Pfizer, Regeneron Pharmaceuticals, Bayer, and other market participants.
Primary research incorporates perspectives from more than 15 Key Opinion Leaders and Subject Matter Experts, including physicians, researchers, professors, and other specialists. Institutions contacted include the American Society of Hematology, the University of Edinburgh, and Aichi Medical University. These insights support validation of epidemiological assumptions, treatment patterns, patient adherence, accessibility challenges, real-world prescribing, therapy switching, and pipeline prioritization.
Qualitative assessment includes SWOT and conjoint analysis based on efficacy, safety, administration frequency, route of administration, order of entry, probability of success, and addressable patient population. The report uses epidemiology-based bottom-up forecasting and an 11-Year Forecast to assess the venous thromboembolism treatment addressable market across North America, Europe, and Asia-Pacific.
Reasons to Access the Venous Thromboembolism Market Report
- Assess current and forecasted venous thromboembolism market opportunities across the 7MM. Understand patient burden, diagnosis trends, treatment practices, and unmet medical needs. Benchmark approved and emerging therapies by clinical profile, uptake potential, and competitive position. Evaluate pricing, access, adherence, and regional commercialization considerations. Identify leading companies, pipeline assets, and potential market disruptors through 2036. Support clinical development, market access, portfolio planning, and launch strategy with expert-validated insights.
Overall, the venous thromboembolism market is positioned for sustained growth through 2036. Rising incidence, broader use of oral anticoagulants, greater disease awareness, and continued therapeutic innovation will support market expansion. ELIQUIS is expected to retain leadership, while factor XI-targeted therapies and novel thrombolytic agents may create new opportunities for patients, clinicians, and pharmaceutical companies.
Key Topics Covered
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
4.1. Upcoming Key Catalyst
4.2. Key Conferences And Meetings
4.3. Key Transactions And Collaborations
4.4. News Flow
5. Epidemiology and Market Methodology of Venous Thromboembolism
6. Venous Thromboembolism Market Overview at a Glance
6.1. Emerging Landscape Analysis (by Molecule Type, Phase, and Route of Administration [ROA])
6.2. Market Share of Venous Thromboembolism by Therapies (%) in the 7MM in 2025
6.3. Market Share of Venous Thromboembolism by Therapies (%) in the 7MM in 2036
7. Disease Background And Overview of Venous Thromboembolism
7.1. Introduction
7.2. Causes
7.3. Signs And Symptoms
7.4. Diagnosis
7.4.1. Differential Diagnosis
7.4.2. Diagnostic Algorithm
7.4.3. Diagnostic Guidelines
7.5. Treatment and Management
7.5.1. Treatment Algorithm
7.5.2. Treatment Guidelines
8. Epidemiology and Patient Population of Venous Thromboembolism
8.1. Key Findings
8.2. Assumption and Rationale
8.3. Total Incident Cases of Venous Thromboembolism in the 7MM
8.4. The United States
8.4.1. Total Incident Cases of Venous Thromboembolism in the United States
8.4.2. Type-specific Incident Cases of Venous Thromboembolism in the United States
8.4.3. Occurrence-specific Incident Cases of Venous Thromboembolism in the United States
8.4.4. Age-specific Incident Cases of Venous Thromboembolism in the United States
8.4.5. Total Prophylactic/Preventive Setting Incident Cases of Venous Thromboembolism in the United States
8.4.6. Total Treated Cases of Venous Thromboembolism in the United States
8.4.7. Total Potential (Mortality and Recurrent adjusted) Cases of Venous Thromboembolism in the United States
8.5. EU4 and the UK
8.5.1. Total Incident Cases of Venous Thromboembolism in EU4 and the UK
8.5.2. Type-specific Incident Cases of Venous Thromboembolism in EU4 and the UK
8.5.3. Occurrence-specific Incident Cases of Venous Thromboembolism in EU4 and the UK
8.5.4. Age-specific Incident Cases of Venous Thromboembolism in EU4 and the UK
8.5.5. Total Prophylactic/Preventive Setting Incident Cases of Venous Thromboembolism in EU4 and the UK
8.5.6. Total Treated Cases of Venous Thromboembolism in EU4 and the UK
8.5.7. Total Potential (Mortality and Recurrent adjusted) Cases of Venous Thromboembolism in EU4 and the UK
8.6. Japan
8.6.1. Total Incident Cases of Venous Thromboembolism in Japan
8.6.2. Type-specific Incident Cases of Venous Thromboembolism in Japan
8.6.3. Occurrence-specific Incident Cases of Venous Thromboembolism in Japan
8.6.4. Age-specific Incident Cases of Venous Thromboembolism in Japan
8.6.5. Total Prophylactic/Preventive Setting Incident Cases of Venous Thromboembolism in Japan
8.6.6. Total Treated Cases of Venous Thromboembolism in Japan
8.6.7. Total Potential (Mortality and Recurrent adjusted) Cases of Venous Thromboembolism in Japan
9. Patient Journey of Venous Thromboembolism
10. Marketed Therapies
10.1. Marketed Competitive Landscape of Venous Thromboembolism
10.2. Apixaban (ELIQUIS): Bristol Myers Squibb
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Other Developmental Activities
10.2.4. Summary of Pivotal Trials
10.2.5. Analyst Views
10.3. Dabigatran etexilate (PRADAXA): Boehringer Ingelheim
10.3.1. Product Description
10.3.2. Regulatory Milestones
10.3.3. Other Developmental Activities
10.3.4. Summary of Pivotal Trials
10.3.5. Analyst Views
11. Emerging Therapies
11.1. Emerging Competitive Landscape of Venous Thromboembolism
11.2. REGN7508: Regeneron Pharmaceuticals
11.2.1. Product Description
11.2.2. Other Developmental Activities
11.2.3. Clinical Development
11.2.3.1. Clinical Trial Information
11.2.4. Safety and Efficacy
11.2.5. Analyst Views
11.3. BAY3018250: Bayer
11.3.1. Product Description
11.3.2. Other Developmental Activities
11.3.3. Clinical Development
11.3.3.1. Clinical Trial Information
11.3.4. Safety and Efficacy
11.3.5. Analyst Views
12. Venous Thromboembolism: Seven Major Market Analysis
12.1. Key Findings
12.2. Market Outlook of Venous Thromboembolism
12.3. Conjoint Analysis of Venous Thromboembolism
12.4. Key Market Forecast Assumptions
12.4.1. Cost Assumptions
12.4.2. Pricing Trends
12.4.3. Analogue Assessment
12.4.4. Launch Year and Therapy Uptakes
12.5. Total Market Size of Venous Thromboembolism in the 7MM
12.6. The United States
12.6.1. Total Market Size of Venous Thromboembolism in the United States
12.6.2. Market Size of Venous Thromboembolism by Therapies in the United States
12.7. EU4 and the UK
12.7.1. Total Market Size of Venous Thromboembolism in EU4 and the UK
12.7.2. Market Size of Venous Thromboembolism by Therapies in EU4 and the UK
12.8. Japan
12.8.1. Total Market Size of Venous Thromboembolism in Japan
12.8.2. Market Size of Venous Thromboembolism by Therapies in Japan
13. Unmet Needs of Venous Thromboembolism
14. SWOT Analysis of Venous Thromboembolism
15. KOL Views of Venous Thromboembolism
15.1. Expert/KOL Interview Highlights
16. Market Access and Reimbursement of Venous Thromboembolism
16.1. The US
16.2. In EU4 and the UK
16.2.1. Germany
16.2.2. France
16.2.3. Italy
16.2.4. Spain
16.2.5. United Kingdom
16.3. Japan
16.4. Summary and Comparison of Market Accesses and Pricing Policy Developments in 2025
16.5. Market Access and Reimbursement of Venous Thromboembolism Therapies
17. Appendix
17.1. Bibliography
17.2. Report Methodology
18. Analyst's Capabilities
19. Disclaimer
20. About the Analyst
List of Tables [35]
List of Figures [35]
A selection of companies mentioned in this report includes, but is not limited to:
- Bristol Myers Squibb Boehringer Ingelheim Pfizer Regeneron Pharmaceuticals Bayer
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment